The discovery that C9orf72 haploinsufficiency contributes to disease pathogenesis and that epigenetic processes mediate this effect offers a unique opportunity for therapeutic development, providing c9FTD/ALS patients with new hope. The gene discussed is C9orf72; the disease is amyotrophic lateral sclerosis.